CDC Panel Shifts Hepatitis B Vaccine Guidance, Favoring Parental Choice
A new recommendation from the centers for Disease Control and Prevention (CDC) emphasizes individualized decision-making regarding the hepatitis B vaccine for newborns.
In a landmark vote on december 5, 2025, the CDC’s Advisory Committee on Immunization Practices (ACIP) voted 8 to 3 to recommend a shift away from universal hepatitis B vaccination at birth. The new guidance prioritizes shared clinical decision-making between parents and healthcare providers, particularly for infants born to mothers who have tested negative for the virus.For thes infants, the committee suggested delaying the initial vaccine dose until at least two months of age.
The move reflects a growing debate over the necessity of the birth dose, given the declining incidence of hepatitis B in the United States. According to the ACIP, this individualized approach means parents and doctors should carefully weigh the benefits and risks of the vaccine, alongside the specific infection risks faced by the child – such as a family member with hepatitis B or frequent contact with individuals from regions where the virus is prevalent.
ACIP also recommended that healthcare providers consider testing antibody levels to hepatitis surface antigen to assess the adequacy of protection following vaccination. This assessment would help determine if subsequent doses are necessary.
The recommendations are designed to maintain consistent coverage across all payment systems, including programs like the vaccines for Children Program, the Children’s Health Insurance Program, Medicaid, and Medicare, as well as private insurance plans offered through the federal Health Insurance Marketplace.Previously, on September 19, 2025, ACIP had already recommended universal testing for the hepatitis B virus during pregnancy, a test covered by all insurance programs.
The vote followed presentations to the committee detailing the current hepatitis B disease burden, vaccine safety data, and immunization policies in other nations. A key presentation by Cynthia Nevison, Ph.D., indicated that the contribution of the universal birth dose to the decline in acute hepatitis B cases since 1985 is likely minimal. Dr. Nevison’s research highlighted significant reductions in transmission through blood transfusions, dialysis, and needle exchange programs. Her analysis also noted that a 2019 study found that approximately 57.9% of births to mothers testing positive for the hepatitis B surface antigen involved women born outside the U.S., primarily from countries with high rates of the virus. That study revealed that 0.5% of all pregnancies in the U.S. are to women who test positive for the hepatitis B surface antigen, representing the most significant risk of newborn infection.
vicky Pebsworth, Ph.D.,RN,Chair of the ACIP Childhood/Adolescent Schedule Workgroup,presented a comparative analysis of global immunization schedules,revealing that the United States’ universal birth dose recommendation is an outlier among developed countries with low hepatitis B prevalence.
“The American people have benefited from the committee’s well-informed, rigorous discussion about the appropriateness of a vaccination in the first few hours of life,” stated a seni
Why, Who, What, and How did it end?
* Why: The CDC panel shifted guidance due to declining hepatitis B incidence in the U.S. and a debate over the necessity of the birth dose. Research suggested the birth dose’s contribution to declining cases was minimal.
